137 related articles for article (PubMed ID: 15476054)
41. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus.
Willis AM; Coulter WA; Fulton CR; Hayes JR; Bell PM; Lamey PJ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Mar; 91(3):317-21. PubMed ID: 11250629
[TBL] [Abstract][Full Text] [Related]
42. Innovative formulation of nystatin particulate systems in toothpaste for candidiasis treatment.
Pinto Reis C; Vasques Roque L; Baptista M; Rijo P
Pharm Dev Technol; 2016; 21(3):282-7. PubMed ID: 25567611
[TBL] [Abstract][Full Text] [Related]
43. Effects of psychological stress and alprazolam on development of oral candidiasis in rats.
Núñez MJ; Balboa J; Riveiro P; Liñares D; Mañá P; Rey-Méndez M; Rodríguez-Cobos A; Suárez-Quintanilla JA; García-Vallejo LA; Freire-Garabal M
Clin Diagn Lab Immunol; 2002 Jul; 9(4):852-7. PubMed ID: 12093685
[TBL] [Abstract][Full Text] [Related]
44. Diversity, frequency and antifungal resistance of Candida species in patients with type 2 diabetes mellitus.
Aitken-Saavedra J; Lund RG; González J; Huenchunao R; Perez-Vallespir I; Morales-Bozo I; Urzúa B; Tarquinio SC; Maturana-Ramírez A; Martos J; Fernandez-Ramires R; Molina-Berríos A
Acta Odontol Scand; 2018 Nov; 76(8):580-586. PubMed ID: 30045641
[TBL] [Abstract][Full Text] [Related]
45. Nystatin pastilles and suspension in the treatment of oral candidosis.
Millns B; Martin MV
Br Dent J; 1996 Sep; 181(6):209-11. PubMed ID: 8885454
[TBL] [Abstract][Full Text] [Related]
46. Antifungal activity, mode of action and anti-biofilm effects of Laurus nobilis Linnaeus essential oil against Candida spp.
Peixoto LR; Rosalen PL; Ferreira GL; Freires IA; de Carvalho FG; Castellano LR; de Castro RD
Arch Oral Biol; 2017 Jan; 73():179-185. PubMed ID: 27771586
[TBL] [Abstract][Full Text] [Related]
47. The in vitro post-antifungal effect of nystatin on Candida species of oral origin.
Ellepola AN; Samaranayake LP
J Oral Pathol Med; 1999 Mar; 28(3):112-6. PubMed ID: 10069538
[TBL] [Abstract][Full Text] [Related]
48. The relative pathogenicity of Candida krusei and C. albicans in the rat oral mucosa.
Samaranayake YH; Wu PC; Samaranayake LP; Ho PL
J Med Microbiol; 1998 Dec; 47(12):1047-57. PubMed ID: 9856640
[TBL] [Abstract][Full Text] [Related]
49. Amplitude-modulated cold atmospheric pressure plasma jet for treatment of oral candidiasis: In vivo study.
Borges AC; Lima GMG; Nishime TMC; Gontijo AVL; Kostov KG; Koga-Ito CY
PLoS One; 2018; 13(6):e0199832. PubMed ID: 29949638
[TBL] [Abstract][Full Text] [Related]
50. Oral candidiasis: effects of antifungal therapy upon clinical signs and symptoms, salivary antibody, and mucosal adherence of Candida albicans.
Epstein JB; Pearsall NN; Truelove EL
Oral Surg Oral Med Oral Pathol; 1981 Jan; 51(1):32-6. PubMed ID: 7007953
[TBL] [Abstract][Full Text] [Related]
51. Carvacrol and eugenol differentially stimulate intracellular Ca2+ mobilization and mitogen-activated protein kinases in Jurkat T-cells and monocytic THP-1 cells.
Chan AS; Pang H; Yip EC; Tam YK; Wong YH
Planta Med; 2005 Jul; 71(7):634-9. PubMed ID: 16041649
[TBL] [Abstract][Full Text] [Related]
52. Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis.
Anwar SK; Elmonaem SNA; Moussa E; Aboulela AG; Essawy MM
Odontology; 2023 Apr; 111(2):350-359. PubMed ID: 36100802
[TBL] [Abstract][Full Text] [Related]
53. Development and In Vivo Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis.
Kong EF; Tsui C; Boyce H; Ibrahim A; Hoag SW; Karlsson AJ; Meiller TF; Jabra-Rizk MA
Antimicrob Agents Chemother; 2016 Feb; 60(2):881-9. PubMed ID: 26596951
[TBL] [Abstract][Full Text] [Related]
54. Comparison of silver-coated dressing (Acticoat®), chlorhexidine acetate 0.5% (Bactigrass®) and nystatin for topical antifungal effect in Candida albicans-contaminated, full-skin-thickness rat burn wounds.
Acar A; Uygur F; Diktaş H; Evinç R; Ulkür E; Oncül O; Görenek L
Burns; 2011 Aug; 37(5):882-5. PubMed ID: 21354707
[TBL] [Abstract][Full Text] [Related]
55. Sub-therapeutic exposure to polyene antimycotics elicits a post-antifungal effect (PAFE) and depresses the cell surface hydrophobicity of oral Candida albicans isolates.
Egusa H; Ellepola AN; Nikawa H; Hamada T; Samaranayake LP
J Oral Pathol Med; 2000 May; 29(5):206-13. PubMed ID: 10801037
[TBL] [Abstract][Full Text] [Related]
56. In vivo photodynamic inactivation of Candida albicans using chloro-aluminum phthalocyanine.
Carmello JC; Alves F; Ribeiro A; Basso FG; de Souza Costa CA; Tedesco AC; Primo FL; Mima EG; Pavarina AC
Oral Dis; 2016 Jul; 22(5):415-22. PubMed ID: 26914185
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo activity of Melaleuca alternifolia mixed with tissue conditioner on Candida albicans.
Catalán A; Pacheco JG; Martínez A; Mondaca MA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Mar; 105(3):327-32. PubMed ID: 18280967
[TBL] [Abstract][Full Text] [Related]
58. Effect of licorice compounds licochalcone A, glabridin and glycyrrhizic acid on growth and virulence properties of Candida albicans.
Messier C; Grenier D
Mycoses; 2011 Nov; 54(6):e801-6. PubMed ID: 21615543
[TBL] [Abstract][Full Text] [Related]
59. Antifungal activity and mode of action of thymol and its synergism with nystatin against Candida species involved with infections in the oral cavity: an in vitro study.
de Castro RD; de Souza TM; Bezerra LM; Ferreira GL; Costa EM; Cavalcanti AL
BMC Complement Altern Med; 2015 Nov; 15():417. PubMed ID: 26601661
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of the antifungal activity of individual and combined monoterpenes against Rhizopus stolonifer and Absidia coerulea.
Zhou L; Zhang Z; Wei M; Xie Y; He S; Shi H; Lin Z
Environ Sci Pollut Res Int; 2019 Mar; 26(8):7804-7809. PubMed ID: 30675711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
